BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 22798675)

  • 41. T-cell receptor gene therapy of established tumors in a murine melanoma model.
    Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
    J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
    Morgan RA; Dudley ME; Yu YY; Zheng Z; Robbins PF; Theoret MR; Wunderlich JR; Hughes MS; Restifo NP; Rosenberg SA
    J Immunol; 2003 Sep; 171(6):3287-95. PubMed ID: 12960359
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Regulatory function for murine intraepithelial lymphocytes. Two subsets of CD3+, T cell receptor-1+ intraepithelial lymphocyte T cells abrogate oral tolerance.
    Fujihashi K; Taguchi T; McGhee JR; Eldridge JH; Bruce MG; Green DR; Singh B; Kiyono H
    J Immunol; 1990 Oct; 145(7):2010-9. PubMed ID: 1975820
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas.
    Kawakami Y; Zakut R; Topalian SL; Stötter H; Rosenberg SA
    J Immunol; 1992 Jan; 148(2):638-43. PubMed ID: 1729379
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes.
    Friedman KM; Prieto PA; Devillier LE; Gross CA; Yang JC; Wunderlich JR; Rosenberg SA; Dudley ME
    J Immunother; 2012 Jun; 35(5):400-8. PubMed ID: 22576345
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhanced T cell maturation and altered lineage commitment in T cell receptor/CD4-transgenic mice.
    Lieberman SA; Spain LM; Wang L; Berg LJ
    Cell Immunol; 1995 Apr; 162(1):56-67. PubMed ID: 7704911
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy.
    Prieto PA; Durflinger KH; Wunderlich JR; Rosenberg SA; Dudley ME
    J Immunother; 2010 Jun; 33(5):547-56. PubMed ID: 20463593
    [TBL] [Abstract][Full Text] [Related]  

  • 49. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.
    Tjin EP; Konijnenberg D; Krebbers G; Mallo H; Drijfhout JW; Franken KL; van der Horst CM; Bos JD; Nieweg OE; Kroon BB; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
    Clin Cancer Res; 2011 Sep; 17(17):5736-47. PubMed ID: 21750202
    [TBL] [Abstract][Full Text] [Related]  

  • 50. TCR-associated zeta-Fc epsilon RI gamma heterodimers on CD4-CD8- NK1.1+ T cells selected by specific class I MHC antigen.
    Curnow SJ; Boyer C; Buferne M; Schmitt-Verhulst AM
    Immunity; 1995 Oct; 3(4):427-38. PubMed ID: 7584134
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix.
    Santin AD; Bellone S; Palmieri M; Bossini B; Roman JJ; Cannon MJ; Bignotti E; Canè S; Pecorelli S
    Gynecol Oncol; 2003 May; 89(2):271-80. PubMed ID: 12713991
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
    Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
    J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
    [TBL] [Abstract][Full Text] [Related]  

  • 53. T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies.
    Straetemans T; Coccoris M; Berrevoets C; Treffers-Westerlaken E; Scholten CE; Schipper D; Ten Hagen TL; Debets R
    Hum Gene Ther; 2012 Feb; 23(2):187-201. PubMed ID: 21958294
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preferential positive selection of T lymphocytes which express two different TCR alpha chains, an endogenous and a transgenic.
    Munthe LA; Sollien A; Dembic Z; Bogen B
    Scand J Immunol; 1995 Dec; 42(6):651-61. PubMed ID: 8552989
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.
    Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Xiang J
    Vaccine; 2012 May; 30(24):3519-25. PubMed ID: 22484292
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR.
    Kuball J; Schmitz FW; Voss RH; Ferreira EA; Engel R; Guillaume P; Strand S; Romero P; Huber C; Sherman LA; Theobald M
    Immunity; 2005 Jan; 22(1):117-29. PubMed ID: 15664164
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Precommitment of CD4+CD8+ thymocytes to either CD4 or CD8 lineages.
    Crompton T; Lees RK; Pircher H; MacDonald HR
    Proc Natl Acad Sci U S A; 1993 Oct; 90(19):8982-6. PubMed ID: 8415641
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of tumor-infiltrating lymphocytes in the treatment of hepatic metastases arising from transgenic intraocular tumors in mice.
    Ma D; Niederkorn JY
    Invest Ophthalmol Vis Sci; 1995 May; 36(6):1067-75. PubMed ID: 7730016
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo.
    Hughes DP; Baskar D; Urban FF; Friedman MS; Braun TM; McDonagh KT
    Cytotherapy; 2005; 7(5):396-407. PubMed ID: 16236629
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.
    Kerkar SP; Sanchez-Perez L; Yang S; Borman ZA; Muranski P; Ji Y; Chinnasamy D; Kaiser AD; Hinrichs CS; Klebanoff CA; Scott CD; Gattinoni L; Morgan RA; Rosenberg SA; Restifo NP
    J Immunother; 2011 May; 34(4):343-52. PubMed ID: 21499127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.